Epigenome-wide association studies (EWAS) have traditionally focused on the association test of single epigenetic markers with complex traits. However, it is possible that multiple cytosine-phosphate-guanine (CpG) sites at the same locus could jointly exert their effects on human traits. Therefore, a region-based test that combines multiple markers could be more powerful. We used 2 different region-based tests to investigate the association between changes in DNA methylation and drug response, including the median methylation level test (MMLT) and sequence kernel association test (SKAT). No genes were found to be significantly associated with the drug response (for triglycerides, the false discovery rate ranged from 0.855 to 0.999; for high-density lipoprotein cholesterol, and the false discovery rate ranged from 0.584 to 0.915). Further evidence is needed to explore potential application of gene-level methylation association analysis.
CITATION STYLE
Wang, B., Destefano, A. L., & Lin, H. (2018). Integrative methylation score to identify epigenetic modifications associated with lipid changes resulting from fenofibrate treatment in families 06 Biological Sciences 0604 Genetics. In BMC Proceedings (Vol. 12). BioMed Central Ltd. https://doi.org/10.1186/s12919-018-0125-x
Mendeley helps you to discover research relevant for your work.